Journal Watch · Clinical Pharmacology & Therapeutics · 2026

Characterization of the Immune Response after Oral Cholera Vaccination (OCV) and Effects of Mycophenolate Mofetil on Priming of this Immune Response-A Randomized, Placebo-Controlled Trial.

Taken together, this study provides a framework for future clinical pharmacology studies building on OCV as a challenge model and for further investigation of specific effects of MMF on mucosal vaccination responses.

Eveleens Maarse BC, In 't Veld AE, Grievink HW et al.Clinical Pharmacology & Therapeutics3 min readPharma relevance 85/100

DOI: 10.1002/cpt.70399PMID: 42482256Study type: randomised / controlled clinical trial

TL;DR

Taken together, this study provides a framework for future clinical pharmacology studies building on OCV as a challenge model and for further investigation of specific effects of MMF on mucosal vaccination responses.

Key findings

  • There were considerable serum IgA and IgG responses after vaccination.
  • MMF-treated volunteers still showed a significant cholera antibody response, though data suggest a potential suppression by MMF without reaching statistical significance.
  • There was no substantial IgA response in saliva.
  • Investigation of PBMCs from OCV-treated participants showed a Th2 skewing with increased ex vivo production of TNF, IL-2, IL-5, IL-13, and IL-22 compared to the placebo group.
  • Taken together, this study provides a framework for future clinical pharmacology studies building on OCV as a challenge model and for further investigation of specific effects of MMF on mucosal vaccination responses.

What they did

Moreover, the study aimed to characterize the immune response provoked by OCV in detail. This randomized, placebo-controlled, single-blind trial included 16 healthy volunteers, each receiving two doses of Dukoral® and an intranasal rechallenge. Outcome measures were serum antibody responses (IgA and IgG) and IgA levels in saliva. Additionally, peripheral blood mononuclear cells (PBMCs) of participants were investigated for ex vivo cytokine production and expression of tissue-specific homing markers after OCV.

Full abstract (original)

Background: Mycophenolate mofetil (MMF) is an immunosuppressive drug widely used by solid organ transplant recipients. Although it is known that MMF suppresses immune responses, its exact effects on specific vaccinations have not been investigated yet. Mucosal vaccinations are increasingly used, such as a cholera vaccination consisting of two oral immunizations (oral cholera vaccination; OCV). This study aimed to investigate the specific immunosuppressive effects of MMF use during the first dose of OCV in a randomized, placebo-controlled trial in healthy volunteers.

What they did: Moreover, the study aimed to characterize the immune response provoked by OCV in detail. This randomized, placebo-controlled, single-blind trial included 16 healthy volunteers, each receiving two doses of Dukoral® and an intranasal rechallenge. Outcome measures were serum antibody responses (IgA and IgG) and IgA levels in saliva. Additionally, peripheral blood mononuclear cells (PBMCs) of participants were investigated for ex vivo cytokine production and expression of tissue-specific homing markers after OCV.

Results & conclusions: There were considerable serum IgA and IgG responses after vaccination. MMF-treated volunteers still showed a significant cholera antibody response, though data suggest a potential suppression by MMF without reaching statistical significance. There was no substantial IgA response in saliva. Investigation of PBMCs from OCV-treated participants showed a Th2 skewing with increased ex vivo production of TNF, IL-2, IL-5, IL-13, and IL-22 compared to the placebo group. Taken together, this study provides a framework for future clinical pharmacology studies building on OCV as a challenge model and for further investigation of specific effects of MMF on mucosal vaccination responses.

Abstract © the authors / Clinical Pharmacology & Therapeutics (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1002/cpt.70399 · PubMed 42482256.

Why it matters for pharma & biotech

  • Directly relevant to teams in vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: vaccines

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Clinical Pharmacology & Therapeutics study find?

Taken together, this study provides a framework for future clinical pharmacology studies building on OCV as a challenge model and for further investigation of specific effects of MMF on mucosal vaccination responses.

What type of study is this?

It is a randomised / controlled clinical trial, published in Clinical Pharmacology & Therapeutics in 2026. Moreover, the study aimed to characterize the immune response provoked by OCV in detail.

Where can I read the original paper?

The original is at the publisher via DOI 10.1002/cpt.70399. PubMed ID: 42482256. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Eveleens Maarse BC, In 't Veld AE, Grievink HW et al.. Characterization of the Immune Response after Oral Cholera Vaccination (OCV) and Effects of Mycophenolate Mofetil on Priming of this Immune Response-A Randomized, Placebo-Controlled Trial.. Clinical Pharmacology & Therapeutics (2026). DOI: 10.1002/cpt.70399.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/characterization-of-the-immune-response-after-oral-cholera-vaccination-o-t70399/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides